Evidence map›Paper›PMID 36372941›Full record

Observational studyAnnals of neurology2023

Cerebral Cortical Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Cristina Valencia-Sanchez, Yong Guo, Karl N Krecke, John J Chen, Vyanka Redenbaugh, Mayra Montalvo, Paul M Elsbernd, Jan-Mendelt Tillema, Sebastian Lopez-Chiriboga, Adrian Budhram and 6 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Annals of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Clinical features of recurrent MOG antibody-associated cortical encephalitis in adults.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  2. Review
  3. Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Review
  4. Article
  5. Article
  6. U-Fiber Enhancement in MOGAD: Extending the Meningo-Cortical Spectrum.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  7. Article
  8. Article
  9. Application of the ADEM definition to cerebral attacks of MOG antibody-associated disease.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
    Article
  10. Article
  11. Multi-tracer PET and MR imaging visualize distinct metabolic and inflammatory profiles in the white matter of NMOSD and MOGAD.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  12. Review
  13. Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Current neurology and neuroscience reports · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

Cristina Valencia-SanchezDepartment of Neurology, Mayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0002-6661-2910
Yong GuoDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Karl N KreckeDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
John J ChenDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Vyanka RedenbaughDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Mayra MontalvoDepartment of Neurology, University of Florida, Gainesville, FL, USA.
Paul M ElsberndBrooke Army Medical Center, San Antonio, TX, USA.
Jan-Mendelt TillemaDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Sebastian Lopez-ChiribogaDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-5653-5600
Adrian BudhramDepartment of Neurology, Western University, London, Ontario, Canada.ORCID 0000-0003-4860-0470
Elia SechiDepartment of Neurology, University of Sassari, Sassari, Italy.
Amy KunchokDepartment of Neurology, Cleveland Clinic, Cleveland, OH, USA.
Divyanshu DubeyDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-4302-4075
Sean J PittockDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6140-5584
Claudia F LucchinettiDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Eoin P FlanaganDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USMayo Clinic in Arizona · USBrooke Army Medical Center · USCleveland Clinic · USJacksonville College · USUniversity of Florida · USUniversity of Sassari · ITWestern University · CA

Funding

Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeuticsR01NS113828 · NINDS · MAYO CLINIC ROCHESTER · PI Eoin P Flanagan · 2020 to 2026
$2.4M
NINDS NIH HHS R01 NS113828NINDS NIH HHS R01NS113828
6 · The paper itself

Abstract

Cerebral cortical encephalitis (CCE) is a recently described myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) phenotype. In this observational retrospective study, we characterized 19 CCE patients (6.7% of our MOGAD cohort). Headache (n = 15, 79%), seizures (n = 13, 68%), and encephalopathy (n = 12, 63%) were frequent. Magnetic resonance imaging revealed unilateral (n = 12, 63%) or bilateral (n = 7, 37%) cortical T2 hyperintensity and leptomeningeal enhancement (n = 17, 89%). N-Methyl-D-aspartate receptor autoantibodies coexisted in 2 of 15 tested (13%). CCE pathology (n = 2) showed extensive subpial cortical demyelination (n = 2), microglial reactivity (n = 2), and inflammatory infiltrates (perivascular, n = 1; meningeal, n = 1). Most received high-dose steroids (n = 17, 89%), and all improved, but 3 had CCE relapses. This study highlights the CCE spectrum and provides insight into its pathogenesis. ANN NEUROL 2023;93:297-302.

Indexed as

EncephalitisAutoantibodiesHumansMagnetic Resonance ImagingMyelin-Oligodendrocyte GlycoproteinRetrospective StudiesAutoantibodiesMyelin-Oligodendrocyte Glycoprotein

Identifiers

PMID36372941
PMCPMC10107670
OpenAlexW4308957368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.